RegeneRx Biopharmaceuticals, Inc. RGRX

Full chart Compare

Set alert

0.00 USD 0.00 (+0.00%)

At closeNov 9, 2026, 4:00 PM EST

0.161 Day range 0.161

0.0002 52-week range 0.163

YTD: +266.67%
1 year: +450.00%

News

3 years ago prnewswire.com RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection,…
3 years ago prnewswire.com RegeneRx Receives Stockholder Approval for Reverse Stock Split ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection,…
3 years ago prnewswire.com RegeneRx To Extend Consent Solicitation Vote ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair,…
5 years ago prnewswire.com Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com RegeneRx Issues Letter To Stockholders ROCKVILLE, Md., July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection,…
5 years ago prnewswire.com RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement ROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement ROCKVILLE, Md., June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial ROCKVILLE, Md., March 18, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection,…
5 years ago prnewswire.com RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection,…
5 years ago prnewswire.com RegeneRx Comments on ARISE-3 Clinical Trial ROCKVILLE, Md., Jan. 26, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection,…